These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22383975)

  • 1. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
    Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
    PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
    Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
    Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
    Krakstad C; Birkeland E; Seidel D; Kusonmano K; Petersen K; Mjøs S; Hoivik EA; Wik E; Halle MK; Øyan AM; Kalland KH; Werner HM; Trovik J; Salvesen H
    PLoS One; 2012; 7(12):e52795. PubMed ID: 23300780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
    Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
    Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
    Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
    Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
    Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
    Catasus L; Gallardo A; Cuatrecasas M; Prat J
    Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
    Konopka B; Janiec-Jankowska A; Czapczak D; Paszko Z; Bidziński M; Olszewski W; Goluda C
    J Cancer Res Clin Oncol; 2007 Jun; 133(6):361-71. PubMed ID: 17219201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
    Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
    Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Jeske YW; Ali S; Byron SA; Gao F; Mannel RS; Ghebre RG; DiSilvestro PA; Lele SB; Pearl ML; Schmidt AP; Lankes HA; Ramirez NC; Rasty G; Powell M; Goodfellow PJ; Pollock PM
    Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
    Byron SA; Gartside MG; Wellens CL; Mallon MA; Keenan JB; Powell MA; Goodfellow PJ; Pollock PM
    Cancer Res; 2008 Sep; 68(17):6902-7. PubMed ID: 18757403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
    Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
    Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
    Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
    PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.